No Data
No Data
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Express News | HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $5 Price Target
Cognition Therapeutics Analyst Ratings
Positive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition Therapeutics
Cognition Therapeutics Provided an Update on Phase 2 'SHINE' Study Analysis
Express News | Cognition Therapeutics Inc -Topline Results in Second Dementia Indication Expected to Be Reported in December 2024
No Data
No Data